Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRES-2: Tafolecimab for Acute High-risk Intracranial or Extracranial Atherosclerosis
NCT07341958Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial in ischemic stroke and Transient Ischemic Attack (TIA) comparing Tafolecimab + Standard Therapy with Placebo + Standard Therapy (2 arms). Primary endpoint: Percentage change in Lipoprotein(a) at 90 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tafolecimab
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT07341958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07341958.